These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34392921)

  • 41. FDG PET-CT of Genitourinary and Gynecologic Tumors: Overcoming the Challenges of Evaluating the Abdomen and Pelvis.
    Lee LK; Kilcoyne A; Goldberg-Stein S; Chow DZ; Lee SI
    Semin Roentgenol; 2016 Jan; 51(1):2-11. PubMed ID: 27020231
    [No Abstract]   [Full Text] [Related]  

  • 42. Detection of extra-regional tumour recurrence with
    Brar H; May T; Tau N; Langer D; MacCrostie P; Han K; Metser U
    Clin Radiol; 2017 Apr; 72(4):302-306. PubMed ID: 28108013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.
    Husain A; Akhurst T; Larson S; Alektiar K; Barakat RR; Chi DS
    Gynecol Oncol; 2007 Jul; 106(1):177-80. PubMed ID: 17477959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PET/MR imaging: current and future applications for cardiovascular disease.
    Naeger DM; Behr SC
    Magn Reson Imaging Clin N Am; 2015 Feb; 23(1):95-103. PubMed ID: 25476678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Role of Computed Tomography and Magnetic Resonance Imaging in Gynecologic Oncology.
    Laifer-Narin SL; Genestine WF; Okechukwu NC; Hecht EM; Newhouse JH
    PET Clin; 2018 Apr; 13(2):127-141. PubMed ID: 29482746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDG PET/CT in monitoring response to treatment in gynecological malignancies.
    Amit A; Person O; Keidar Z
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):17-22. PubMed ID: 23299090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluorodeoxyglucose positron emission tomography/magnetic resonance imaging: current status, future aspects.
    Rakheja R; Chandarana H; Ponzo F; Seltzer AL; Beltran LS; Geppert C; Friedman KP
    PET Clin; 2014 Apr; 9(2):237-52. PubMed ID: 25030285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PET/Computed Tomography and PET/MR Imaging: Basic Principles, Methodology, and Imaging Protocol for Musculoskeletal Applications.
    Parghane RV; Basu S
    PET Clin; 2018 Oct; 13(4):459-476. PubMed ID: 30219182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The reproductive tract.
    Jadvar H; Conti PS
    Semin Nucl Med; 2004 Oct; 34(4):262-73. PubMed ID: 15493004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders.
    Angelini A; Castellucci P; Ceci F
    PET Clin; 2019 Jan; 14(1):183-191. PubMed ID: 30420219
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multimodality Imaging of Uterine Cervical Malignancies.
    Mansoori B; Khatri G; Rivera-Colón G; Albuquerque K; Lea J; Pinho DF
    AJR Am J Roentgenol; 2020 Aug; 215(2):292-304. PubMed ID: 32551909
    [No Abstract]   [Full Text] [Related]  

  • 52. The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies.
    Grisaru D; Almog B; Levine C; Metser U; Fishman A; Lerman H; Lessing JB; Even-Sapir E
    Gynecol Oncol; 2004 Sep; 94(3):680-4. PubMed ID: 15350358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pitfalls in [¹⁸F]FDG PET imaging in gynecological malignancies.
    Hernandez Pampaloni M; Facchetti L; Nardo L
    Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):124-38. PubMed ID: 26937887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PET/CT imaging in gynecologic malignancies: a critical overview of its clinical impact and our retrospective single center analysis.
    Dalla Palma M; Gregianin M; Fiduccia P; Evangelista L; Cervino AR; Saladini G; Borgato L; Nicoletto MO; Zagonel V
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):84-98. PubMed ID: 22245509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
    Kitajima K; Miyoshi Y
    Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positron emission tomography application for gynecologic tumors.
    Nakamoto Y; Saga T; Fujii S
    Int J Gynecol Cancer; 2005; 15(5):701-9. PubMed ID: 16174216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gynecological cancers.
    Avril N; Gourtsoyianni S; Reznek R
    Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiographic imaging in gynecologic oncology.
    Soper JT
    Clin Obstet Gynecol; 2001 Sep; 44(3):485-94. PubMed ID: 11685874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extraovarian primary peritoneal carcinoma: staging with 18F-FDG PET/CT.
    Rakheja R; Makis W; Hickeson M
    Abdom Imaging; 2012 Apr; 37(2):304-8. PubMed ID: 21394599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.